Literature DB >> 17977977

Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix.

Dror Kolodkin-Gal1, Gideon Zamir, Yair Edden, Eli Pikarsky, Alon Pikarsky, Hillel Haim, Yosef S Haviv, Amos Panet.   

Abstract

Viral therapy of cancer (viral oncolysis) is dependent on selective destruction of the tumor tissue compared with healthy tissues. Several factors, including receptor expression, extracellular components, and intracellular mechanisms, may influence viral oncolysis. In the present work, we studied the potential oncolytic activity of herpes simplex virus type 1 (HSV-1), using an organ culture system derived from colon carcinoma and healthy colon tissues of mouse and human origin. HSV-1 infected normal colons ex vivo at a very low efficiency, in contrast to high-efficiency infection of colon carcinoma tissue. In contrast, adenoviral and lentiviral vectors infected both tissues equally well. To investigate the mechanisms underlying the preferential affinity of HSV-1 for the carcinoma tissue, intracellular and extracellular factors were investigated. Two extracellular components, collagen and mucin molecules, were found to restrict HSV-1 infectivity in the healthy colon. The mucin layer of the healthy colon binds to HSV-1 and thereby blocks viral interaction with the epithelial cells of the tissue. In contrast, colon carcinomas express small amounts of collagen and mucin molecules and are thus permissive to HSV-1 infection. In agreement with the ex vivo system, HSV-1 injected into a mouse colon carcinoma in vivo significantly reduced the volume of the tumor. In conclusion, we describe a novel mechanism of viral selectivity for malignant tissues that is based on variance of the extracellular matrix between tumor and healthy tissues. These insights may facilitate new approaches to the application of HSV-1 as an oncolytic virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977977      PMCID: PMC2224594          DOI: 10.1128/JVI.01769-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4.

Authors:  Luis M Schang; Andrew Bantly; Priscilla A Schaffer
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

2.  Early herpes simplex virus type 1 infection is dependent on regulated Rac1/Cdc42 signalling in epithelial MDCKII cells.

Authors:  Sven Hoppe; Mario Schelhaas; Verena Jaeger; Timo Liebig; Philipp Petermann; Dagmar Knebel-Mörsdorf
Journal:  J Gen Virol       Date:  2006-12       Impact factor: 3.891

3.  Adsorption of cationized bovine serum albumin onto epithelial crypt fractions of the rat colon.

Authors:  S Blau; N Levin; B Schwartz; A Rubinstein
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

4.  Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

5.  Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

Authors:  Victor W van Beusechem; Jacques Grill; D C Jeroen Mastenbroek; Thomas J Wickham; Peter W Roelvink; Hidde J Haisma; Martine L M Lamfers; Clemens M F Dirven; Herbert M Pinedo; Winald R Gerritsen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Authors:  Anna Kanerva; Minghui Wang; Gerd J Bauerschmitz; John T Lam; Renee A Desmond; Snehal M Bhoola; Mack N Barnes; Ronald D Alvarez; Gene P Siegal; David T Curiel; Akseli Hemminki
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

7.  Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.

Authors:  N Kuriyama; H Kuriyama; C M Julin; K R Lamborn; M A Israel
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Regulation of herpes simplex virus 1 replication using tumor-associated promoters.

Authors:  John T Mullen; Hideki Kasuya; Sam S Yoon; Nancy M Carroll; Timothy M Pawlik; Soundararajalu Chandrasekhar; Hideo Nakamura; James M Donahue; Kenneth K Tanabe
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

9.  Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Authors:  Yosef S Haviv; Jerry L Blackwell; Anna Kanerva; Peter Nagi; Victor Krasnykh; Igor Dmitriev; Minghui Wang; Seiji Naito; Xiaosheng Lei; Akseli Hemminki; Delicia Carey; David T Curiel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 10.  Altered mucin expression in the gastrointestinal tract: a review.

Authors:  J R Jass; M D Walsh
Journal:  J Cell Mol Med       Date:  2001 Jul-Sep       Impact factor: 5.310

View more
  18 in total

1.  Different modes of herpes simplex virus type 1 spread in brain and skin tissues.

Authors:  Yael Tsalenchuck; Tomer Tzur; Israel Steiner; Amos Panet
Journal:  J Neurovirol       Date:  2014-01-10       Impact factor: 2.643

2.  A single-amino-acid substitution in herpes simplex virus 1 envelope glycoprotein B at a site required for binding to the paired immunoglobulin-like type 2 receptor alpha (PILRalpha) abrogates PILRalpha-dependent viral entry and reduces pathogenesis.

Authors:  Jun Arii; Jing Wang; Tomomi Morimoto; Tadahiro Suenaga; Hiroomi Akashi; Hisashi Arase; Yasushi Kawaguchi
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 3.  A common neuronal response to alphaherpesvirus infection.

Authors:  Moriah L Szpara; Oren Kobiler; Lynn W Enquist
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

4.  Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture.

Authors:  Yiska Weisblum; Amos Panet; Zichria Zakay-Rones; Ronit Haimov-Kochman; Debra Goldman-Wohl; Ilana Ariel; Haya Falk; Shira Natanson-Yaron; Miri D Goldberg; Ronit Gilad; Nell S Lurain; Caryn Greenfield; Simcha Yagel; Dana G Wolf
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 5.  Targeting Persistent Biofilm Infections: Reconsidering the Topography of the Infection Site during Model Selection.

Authors:  Ilana Kolodkin-Gal; Malena Cohen-Cymberknoh; Gideon Zamir; Igor Tsesis; Eyal Rosen
Journal:  Microorganisms       Date:  2022-06-06

6.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

7.  Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

Authors:  B J Passer; C-l Wu; S Wu; S D Rabkin; R L Martuza
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

8.  Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.

Authors:  Nirmala Parajuli; Wolfgang Doppler
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-16       Impact factor: 2.416

9.  Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Dror Kolodkin-Gal; Sandrine L Hulot; Birgit Korioth-Schmitz; Randi B Gombos; Yi Zheng; Joshua Owuor; Michelle A Lifton; Christian Ayeni; Robert M Najarian; Wendy W Yeh; Mohammed Asmal; Gideon Zamir; Norman L Letvin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  Mechanisms of foot-and-mouth disease virus tropism inferred from differential tissue gene expression.

Authors:  James J Zhu; Jonathan Arzt; Michael C Puckette; George R Smoliga; Juan M Pacheco; Luis L Rodriguez
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.